AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31839310 — intervention group
Group type: EXPERIMENTAL
Intervention: ANFIS-ICA
Number of subjects: 0
Study 31839310 — intervention group
Group type: EXPERIMENTAL
Intervention: ANFIS-PSO
Number of subjects: 0
Study 31839310 — intervention group
Group type: COMPARATOR
Intervention: Standalone ANFIS model
Number of subjects: 0
Study 30851066 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 1.5 mg/kg PO q12h for 14 days, followed by 2 mg telmisartan/kg PO q24h
Number of subjects: 221
Study 30851066 — intervention group
Group type: COMPARATOR
Intervention: Placebo equivalent volume
Number of subjects: 221
Study 29798560 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (ACB)
Number of subjects: 60
Study 29798560 — intervention group
Group type: COMPARATOR
Intervention: Single shot adductor canal block (ACB)
Number of subjects: 60
Study 25399481 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid 15% gel (AzA) for 9 months (AzA9M)
Number of subjects: 55
Study 25399481 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid 15% gel (AzA) for 3 months followed by observational phase (AzA3M)
Number of subjects: 55
Study 25399481 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel (AD9M) for 9 months
Number of subjects: 55
Study 23398957 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention alone
Number of subjects: 300
Study 23398957 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion and exercise intervention
Number of subjects: 300
Study 23398957 — intervention group
Group type: COMPARATOR
Intervention: Usual community care and delayed health promotion (control)
Number of subjects: 300
Study 16963035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/d for 12 months
Number of subjects: 36
Study 16963035 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 36
Study 14767410 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/day divided into 4 doses of 5 g each)
Number of subjects: 20
Study 14767410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10397206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole (400 mg per day)
Number of subjects: 49
Study 10397206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8894809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 58
Study 8894809 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 58
Study 1518122 — intervention group
Group type: EXPERIMENTAL
Intervention: Panipenem/betamipron (PAPM/BP) 10 mg/10 mg/kg
Number of subjects: 17
Study 1518122 — intervention group
Group type: EXPERIMENTAL
Intervention: Panipenem/betamipron (PAPM/BP) 20 mg/20 mg/kg
Number of subjects: 17
Study 1518122 — intervention group
Group type: EXPERIMENTAL
Intervention: Panipenem/betamipron (PAPM/BP)
Number of subjects: 17
Study 6412270 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT)
Number of subjects: 5
Study 6412270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 5
Study 6412270 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) during treatment
Number of subjects: 5
Study 6412270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) during treatment
Number of subjects: 5
Study 31494058 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (n=82) - received high-carotenoid FVs and weekly FV education
Number of subjects: 209
Study 31494058 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (n=61) - received high-carotenoid FVs
Number of subjects: 209
Study 31494058 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n=66) - received neither FVs nor education
Number of subjects: 209
Study 30921297 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment with serious adverse events (SAEs)
Number of subjects: 286
Study 30921297 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment without serious adverse events (SAEs)
Number of subjects: 286
Study 30921297 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (both with and without SAEs)
Number of subjects: 286
Study 30921297 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 286
Study 27880946 — intervention group
Group type: EXPERIMENTAL
Intervention: DP001
Number of subjects: 62
Study 27880946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 27880946 — intervention group
Group type: EXPERIMENTAL
Intervention: DP001 (previously treated with cinacalcet plus active vitamin D)
Number of subjects: 62
Study 27880946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (previously treated with cinacalcet plus active vitamin D)
Number of subjects: 62
Study 25766591 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinum toxin (BoNTA) injected unilaterally in the corrugator muscle
Number of subjects: 5
Study 22715124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stress management and exercise (SMEX)
Number of subjects: 286
Study 22715124 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management (SM)
Number of subjects: 286
Study 20717045 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 45
Study 20717045 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin enteric-coated 81 mg once daily
Number of subjects: 45
Study 18930599 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy (Genotropin; Pfizer) for 6 months
Number of subjects: 22
Study 18930599 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 22
Study 18930599 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline conditions (GH deficient females with Sheehan's syndrome)
Number of subjects: 22
Study 17084630 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic corset
Number of subjects: 11
Study 17084630 — intervention group
Group type: COMPARATOR
Intervention: No corset (control)
Number of subjects: 11
Study 15197122 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural continual intermittent boluses (CIB)
Number of subjects: 42
Study 15197122 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 42
Study 11339777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg x kg(‐1) cisatracurium at the adducting laryngeal muscles
Number of subjects: 24
Study 11339777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg x kg(‐1) cisatracurium at the diaphragm
Number of subjects: 24
Study 11339777 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring site (adductor pollicis muscle)
Number of subjects: 24
Study 11339777 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel paravertebral site
Number of subjects: 24
Study 9039832 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitute (sugar and coloring)
Number of subjects: 139
Study 9039832 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitute (sugar and coloring) in anemic children
Number of subjects: 139
Study 9039832 — intervention group
Group type: COMPARATOR
Intervention: Control (continuation of coffee) in nonanemic children
Number of subjects: 139
Study 9039832 — intervention group
Group type: COMPARATOR
Intervention: Control (continuation of coffee) in anemic children
Number of subjects: 139
Study 8179147 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive intra-operative suggestions
Number of subjects: 60
Study 2465747 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I: Intravenous cisplatin (100-150 mg/m2 on day 1), intramuscular bleomycetin (10 mg on days 2-4), intravenous 5-fluorouracil (400 mg/m2 on days 2-4)
Number of subjects: 22
Study 2465747 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II: Intramuscular bleomycetin (10 mg on days 1-3), intravenous 5-fluorouracil (400 mg/m2 on days 1-3), intravenous cisplatin (100-150 mg/m2 on day 4)
Number of subjects: 22
Study 30106529 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step oral hygiene sequence: 0.454% stannous fluoride dentifrice followed by 3.0% hydrogen peroxide whitening gel
Number of subjects: 44
Study 30106529 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine gluconate oral rinse and 0.76% sodium monofluorophosphate dentifrice
Number of subjects: 44
Study 27278933 — intervention group
Group type: EXPERIMENTAL
Intervention: JADE with nurse-coordinated follow-up visits
Number of subjects: 3586
Study 27278933 — intervention group
Group type: COMPARATOR
Intervention: DIAMOND
Number of subjects: 3586
Study 26637482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii multiglycosides (TWG) combined with prednisone
Number of subjects: 53
Study 26637482 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC) combined with prednisone
Number of subjects: 53
Study 26637482 — intervention group
Group type: EXPERIMENTAL
Intervention: TWG
Number of subjects: 53
Study 26637482 — intervention group
Group type: COMPARATOR
Intervention: TAC
Number of subjects: 53
Study 23216100 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical epidural of preservative‐free morphine and dexmedetomidine administered via gel foam
Number of subjects: 30
Study 23216100 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hydromorphone postoperatively
Number of subjects: 30
Study 23216100 — intervention group
Group type: EXPERIMENTAL
Intervention: Both forms of analgesia (topical epidural and hydromorphone)
Number of subjects: 30
Study 21967492 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 480
Study 21967492 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 480
Study 18463550 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed measurement in patients requiring physical assistance to walk (n=13)
Number of subjects: 35
Study 18463550 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed measurement in patients who can walk without physical assistance (n=22)
Number of subjects: 35
Study 18463550 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed measurement for all subjects combined (n=35)
Number of subjects: 35
Study 16540840 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated drink (5 mg x kg(‐1))
Number of subjects: 52
Study 16540840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 12959740 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) therapy
Number of subjects: 18
Study 12959740 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched controls
Number of subjects: 18
Study 10719310 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 86
Study 10719310 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE determination for hazelnut (positive CAP response >/=0.7 kU/L)
Number of subjects: 86
Study 10719310 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tests with commercial hazelnut extract
Number of subjects: 86
Study 10719310 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tests with natural food
Number of subjects: 86
Study 9202559 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 53
Study 9202559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 1527539 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanutin capsules
Number of subjects: 17
Study 1527539 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin BP tablets (Regent Laboratories)
Number of subjects: 17
Study 1527539 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanutin Infatabs
Number of subjects: 17
Study 1527539 — intervention group
Group type: COMPARATOR
Intervention: Generic 100 mg tablets
Number of subjects: 17
Study 3893025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1% plain
Number of subjects: 1048
Study 3893025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1% with epinephrine
Number of subjects: 1048
Study 3893025 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% plain
Number of subjects: 1048
Study 31066987 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes (0, 18, or 36 mg/ml nicotine)
Number of subjects: 15
Study 31066987 — intervention group
Group type: COMPARATOR
Intervention: Own cigarettes
Number of subjects: 15
Study 30304141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecobalamin (500 µg three times a day)
Number of subjects: 224
Study 30304141 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 224
Study 27382813 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg.kg‐1 oxycodone intravenously 10 min prior to the operation for 2 min
Number of subjects: 60
Study 27382813 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline intravenously
Number of subjects: 60
Study 24215554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand exercises and a soft prefabricated thumb orthosis
Number of subjects: 59
Study 24215554 — intervention group
Group type: COMPARATOR
Intervention: Hand exercises only (control group)
Number of subjects: 59
Study 22309404 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA) with stimulation
Number of subjects: 65
Study 22309404 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 65
Study 22309404 — intervention group
Group type: EXPERIMENTAL
Intervention: sVA (VA with stimulation)
Number of subjects: 65
Study 22309404 — intervention group
Group type: EXPERIMENTAL
Intervention: nsVA (VA without stimulation)
Number of subjects: 65
Study 20056782 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured functional assessments by GPs
Number of subjects: 57
Study 20056782 — intervention group
Group type: COMPARATOR
Intervention: Usual assessment of functional ability by GPs
Number of subjects: 57
Study 18076539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone monotherapy (57.3 +/- 33.9 mg/day)
Number of subjects: 21
Study 16251309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 100 mg/day (100 mg initial dose, then 50 mg intravenously twice daily)
Number of subjects: 546
Study 16251309 — intervention group
Group type: COMPARATOR
Intervention: Combination of vancomycin 2 g/day (1 g intravenously twice daily) and aztreonam 4 g/day (2 g intravenously twice daily)
Number of subjects: 546
Study 16251309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 100 mg/day
Number of subjects: 546
Study 16251309 — intervention group
Group type: COMPARATOR
Intervention: Combination of vancomycin and aztreonam
Number of subjects: 546
Study 11867387 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (25 mg administered randomly and blindly before cooling)
Number of subjects: 7
Study 11867387 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (25 mg administered IV after 10 min of shivering)
Number of subjects: 7
Study 11867387 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (during shivering)
Number of subjects: 7
Study 11867387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered randomly and blindly before cooling)
Number of subjects: 7
Study 10597551 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms.kg‐1
Number of subjects: 40
Study 10597551 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 2 mg.kg‐1
Number of subjects: 40
Study 8531933 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine treatment course 1
Number of subjects: 60
Study 8531933 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine treatment course 2
Number of subjects: 60
Study 8531933 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine treatment course 3
Number of subjects: 60
Study 8531933 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine treatment course 4
Number of subjects: 60
Study 2386275 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 65
Study 2386275 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 65
Study 7358867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (Acupan)
Number of subjects: 196
Study 7358867 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (Benadryl)
Number of subjects: 196
Study 7358867 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 196
Study 7358867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 7358867 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Nefopam
Number of subjects: 196
Study 7358867 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 196
Study 7358867 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nefopam
Number of subjects: 196
Study 7358867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 196
Study 29743105 — intervention group
Group type: EXPERIMENTAL
Intervention: Good School Toolkit intervention
Number of subjects: 1921
Study 29743105 — intervention group
Group type: EXPERIMENTAL
Intervention: Good School Toolkit exposure
Number of subjects: 1921
Study 29743105 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a 'low' number of program school‐led activities
Number of subjects: 1921
Study 29743105 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher Toolkit exposure
Number of subjects: 1921
Study 29743105 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual factors associated with Toolkit exposure
Number of subjects: 1921
Study 29743105 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention risk factors
Number of subjects: 1921
Study 28034969 — intervention group
Group type: EXPERIMENTAL
Intervention: New learning tool for needle insertion accuracy skills (using two video cameras, a monitor, and an ultrasound machine)
Number of subjects: 30
Study 28034969 — intervention group
Group type: COMPARATOR
Intervention: Traditional practice methods (control group)
Number of subjects: 30
Study 28034969 — intervention group
Group type: EXPERIMENTAL
Intervention: New learning tool for inexperienced participants
Number of subjects: 30
Study 28034969 — intervention group
Group type: COMPARATOR
Intervention: Traditional practice methods for experienced participants
Number of subjects: 30
Study 26178495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin plus octreotide
Number of subjects: 120
Study 26178495 — intervention group
Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 120
Study 22706167 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink (daily)
Number of subjects: 54
Study 22706167 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 54
Study 21925126 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 207127 400 mg 3 times daily plus 120 mg BI 201335 once daily and 1000 to 1200 mg/day ribavirin
Number of subjects: 32
Study 21925126 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 207127 600 mg 3 times daily plus 120 mg BI 201335 once daily and 1000 to 1200 mg/day ribavirin
Number of subjects: 32
Study 17581594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg
Number of subjects: 65
Study 17581594 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 65
Study 17581594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 16969289 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) group
Number of subjects: 108
Study 16969289 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) group
Number of subjects: 108
Study 16969289 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 12037783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 1,000 mg followed by a 6-day taper from 200 to 20 mg/d
Number of subjects: 38
Study 12037783 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone 1,000 mg for three consecutive days
Number of subjects: 38
Study 9648325 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Zebra Tarantula placed next to the stimulus light by the door (threat and safety/escape coincide)
Number of subjects: 0
Study 9648325 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Zebra Tarantula placed next to the stimulus light by the wall (threat and safety/escape divided)
Number of subjects: 0
Study 9648325 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition (control group)
Number of subjects: 0
Study 7866361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile (NHP)
Number of subjects: 0
Study 2760497 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric microbial colonization
Number of subjects: 40
Study 4564764 — intervention group
Group type: EXPERIMENTAL
Intervention: Orudis
Number of subjects: 88
Study 4564764 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 88
Study 7351677 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental albumin infusion (31 gm during operation followed by 150 gm/day for 5 days)
Number of subjects: 94
Study 7351677 — intervention group
Group type: COMPARATOR
Intervention: No albumin (control group)
Number of subjects: 94
Study 29953340 — intervention group
Group type: COMPARATOR
Intervention: Bleaching with 40% hydrogen peroxide gel (Opalescence Boost, Ultradent)
Number of subjects: 240
Study 29953340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching + application of calcium silicate/phosphate gel (Regenerate Serum, Unilever - Rs)
Number of subjects: 240
Study 29953340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching + 2% sodium fluoride gel
Number of subjects: 240
Study 29953340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching + remineralizing gel (Regenerate Serum)
Number of subjects: 240
Study 29953340 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushed with Regenerate toothpaste
Number of subjects: 240
Study 29953340 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushed with Close Up toothpaste
Number of subjects: 240
Study 26403322 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 442
Study 26403322 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotics (APs)
Number of subjects: 442